Zoetis (NYSE:ZTS) Updates FY 2025 Earnings Guidance

Zoetis (NYSE:ZTS) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.000-6.100 for the period, compared to the consensus EPS estimate of 6.300. The company issued revenue guidance of $9.2 billion-$9.4 billion, compared to the consensus revenue estimate of $9.6 billion.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZTS. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Piper Sandler lowered their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Finally, Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $214.90.

Zoetis Price Performance

Shares of NYSE ZTS opened at $157.54 on Friday. Zoetis has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company’s 50-day moving average is $168.89 and its 200 day moving average is $178.98. The stock has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, sell-side analysts expect that Zoetis will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.